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Abstract
AIM
To directly compare the efficacy and toxicity of standard-
dose FOLFIRINOX (sFOLFIRINOX) and modified-dose 
FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) 
for pancreatic cancer.
METHODS
One hundred and thirty pancreatic cancer patients 
who received sFOLFIRINOX (n = 88) or mFOLFIRINOX 
(n  = 42) as their first-line chemotherapy from January 
2013 to July 2017 were retrospectively reviewed. For 
efficacy analysis, the objective response rate (ORR), 
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disease control rate (DCR), progression-free survival 
(PFS), and overall survival (OS) were evaluated and 
compared using Pearson’s chi-square test, Kaplan-Meier 
plot and log-rank test. The adverse events (AEs) were 
evaluated, and severe (≥ grade 3) AEs rates of the two 
groups were compared for toxicity analysis.
RESULTS
The mFOLFIRINOX group included more female pati-
ents (30.7% vs  57.1%; P  = 0.004) and older patients 
[age (median), 57 vs  63.5; P  = 0.018] than the 
sFOLFIRINOX group. In the efficacy analysis, the ORR 
and DCR were not significantly different between the 
two groups (ORR: 39.8% vs  35.7%; P  = 0.656; DCR: 
80.7% vs  83.3%; P  = 0.716). The median PFS and OS 
were also not different between the groups (PFS: 8.7 
mo vs  8.1 mo, P  = 0.272; OS: 13.9 mo vs  13.7 mo, P  
= 0.476). In the safety analysis with severe AEs, the 
rates of neutropenia (83.0% vs  66.7%; P  = 0.044), 
anorexia (48.9% vs  28.6%; P  = 0.029) and diarrhea 
(13.6% vs  0.0%; P  = 0.009) were markedly lower in 
the mFOLFIRINOX group.
CONCLUSION
mFOLFIRINOX showed comparable efficacy but better 
safety compared to sFOLFIRINOX. If clinically necessary, 
initiating FOLFIRINOX with 75% of the standard-dose 
can alleviate toxicity concerns without compromising 
efficacy.
Key words: Dose modification; Adverse event; Pancreatic 
cancer; Adenocarcinoma; FOLFIRINOX; Chemotherapy
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Although the efficacy of FOLFIRINOX for 
pancreatic cancer has been well demonstrated, its re-
latively high toxicity rate is an important concern. We 
aimed to directly compare the efficacy and toxicity 
of standard-dose FOLFIRINOX and modified-dose 
FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) 
for pancreatic cancer. One hundred and thirty patients 
with pancreatic cancer (standard: 88 vs  modified: 42) 
were reviewed retrospectively. Response rates, pro-
gression-free survival, and overall survival were not dif-
ferent between both groups. However, severe adverse 
events such as neutropenia, anorexia and diarrhea 
were significantly lower in the mFOLFIRINOX group. If 
clinically necessary, initiating FOLFIRINOX with 75% 
of the standard-dose can alleviate toxicity concerns 
without compromising efficacy.
Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song 
SY, Park JY. Comparison of efficacy and safety between 
standard-dose and modified-dose FOLFIRINOX as a first-
line treatment of pancreatic cancer. World J Gastrointest Oncol 
2018; 10(11): 421-430  Available from: URL: http://www.
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INTRODUCTION
Pancreatic cancer (PC) is the fourth-most common cause 
of cancer deaths estimated in the United States[1]. It is 
also reported as the fifth-most common cause of cancer-
related deaths in South Korea[2]. Despite the introduction 
of several novel regimens, the five-year survival rate for 
all stages of PC remains around ten percent[1,2]. These 
statistics are based on the fact that < 20% of newly 
diagnosed PC cases are suitable candidates for surgical 
resection, while disseminated disease was noted in > 
50% of new cases[1]. 
Ever since the survival benefit of gemcitabine in 
patients with advanced PC was reported, gemcitabine-
based regimens have been primarily used for > twenty 
years[3-6]. Recently, a non-gemcitabine-based combin-
ation regimen comprising folinic acid (FA), 5-fluorouracil 
(5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) was 
introduced for metastatic PC (MPC). In the PRODIGE4/
ACCORD11 randomized phase Ⅲ trial, FOLFIRINOX was 
associated with a significant survival benefit compared 
to gemcitabine monotherapy as the first-line therapy 
for patients with MPC[7]. Thereafter, several studies 
were conducted to determine the role of FOLFIRINOX 
in locally advanced PC (LAPC) or borderline resectable 
PC (BRPC), and meta-analysis reports showed promi-
sing improvements in median survivals and resection 
rates[8,9]. Consequently, FOLFIRINOX is recommended 
as a preferred front-line therapy for MPC in major up-
to-date guidelines and on the list of options for BRPC 
or LAPC, although prospective randomized data are still 
lacking[10-12].
However, the relatively high toxicity of FOLFIRINOX 
is still a concern. In the PRODIGE4/ACCORD11 trial, 
FOLFIRINOX showed higher severe toxicity rates than 
gemcitabine, particularly for grade three or four neu-
tropenia in 45.7% of patients[7]. The National Com-
prehensive Cancer Network guidelines for PC restrict 
FOLFIRINOX to patients with Eastern Cooperative 
Oncology Group performance status (ECOG-PS) 0 or 
1[12]. Owing to the high toxicity profile of FOLFIRINOX, 
several retrospective studies and phase Ⅱ trials using 
modified-dose FOLFIRINOX (mFOLFIRINOX) were perfor-
med with variable modification strategies. This rese-
arch showed improved safety profiles and comparable 
efficacy[13-17]. Nevertheless, clinical feasibility or optimal 
strategy for dose-modification of FOLFIRINOX still re-
mains unclear, since previous studies on mFOLFIRINOX 
indirectly compared their results to those of the PR-
ODIGE4/ACCORD11 trial. Direct comparative study 
between standard-dose FOLFIRINOX (sFOLFIRINOX) 
and mFOLFIRINOX is still lacking. Therefore, in this stu-
dy, we directly compared the therapeutic efficacy and 
safety of sFOLFIRINOX and mFOLFIRINOX as first-line 
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chemotherapies for PC.
MATERIALS AND METHODS
Patient selection
All patients diagnosed with PC who received FOLFIRINOX 
as their first-line chemotherapy in Severance Hospital 
from January 2013 to July 2017 were retrospectively 
reviewed. The inclusion criteria were as follows: (1) 
patients over 19 years of age; (2) histologically- or cy-
tologically-proven pancreatic adenocarcinoma; and (3) 
at least one measurable lesion in accordance with the 
Response Evaluation Criteria in Solid Tumors (RECIST), 
version 1.1[18]. The exclusion criteria were as follows: 
(1) discontinued FOLFIRINOX for any reason before the 
first response evaluation; (2) dose adjustment in the 
first cycle other than 75% of the standard-dose; (3) 
did not start the first cycle of FOLFIRINOX in Severance 
Hospital; (4) diagnosed other active malignancy at the 
same time as PC diagnosis; (5) administered another 
agent in combination with FOLFIRINOX; and (6) regu-
larly administered granulocyte colony stimulating factor 
(G-CSF) for primary prophylaxis. All patients who met 
the inclusion criteria and did not meet the exclusion 
criteria were identified. These patients were divided 
into sFOLFIRINOX and mFOLFIRINOX groups according 
to their starting dose of FOLFIRINOX. 
Work-up and treatment
Pretreatment assessment was conducted for all patients. 
Appropriate imaging modalities were used for staging 
work-up, as needed. The specimen for histological or 
cytological confirmation of malignancy was obtained 
by endoscopic ultrasonography-guided fine needle aspir-
ation, percutaneous biopsy, or exploratory laparotomy, 
as indicated. For each patient, the attending physician 
made a clinical decision on whether the first cycle 
should be initiated with sFOLFIRINOX or mFOLFIRINOX. 
sFOLFIRINOX comprised a 2 h intravenous infusion 
(IVF) of oxaliplatin 85 mg/m2, followed by a 90 min IVF 
of irinotecan 180 mg/m2. FA 400 mg/m2 IVF was perfor-
med over 2 h after termination of irinotecan infusion. 
This was followed by a 5-FU 400 mg/m2 bolus and 2400 
mg/m2 IVF for 46 h. Patients who received a standard 
dose at the first cycle were grouped as sFOLFIRINOX. 
Patients who started with a 75% of standard-dose 
based on the decision of the attending physician were 
grouped as mFOLFIRINOX. All patients were regularly 
administered 0.25 mg of palonosetron 30 min before 
oxaliplatin infusion for emesis prophylaxis. G-CSF was 
not used for primary prophylaxis of neutropenia, and was 
administered when grade three or four neutropenia or 
neutropenic fever occurred. FOLFIRINOX was repeated 
every 2 wk until evidence of progressive disease (PD), 
significant deterioration of patient condition, or patient 
unwillingness. Dose reduction or delay was at the treating 
physician’s discretion and fully considered if the patient 
did not appear to tolerate the dosage of the previous 
cycle.
Assessment of treatment efficacy
Primary endpoints of this study were objective response 
rate (ORR) and disease control rate (DCR). Secondary 
endpoints were progression-free survival (PFS) and 
overall survival (OS). Treatment response was evaluat-
ed after every four cycles using computed tomography 
or magnetic resonance image. All imaging modalities 
were conducted and reviewed in compliance with the 
institutional standard protocols. According to the RECIST, 
responses were reported by a professional radiologist, 
and the final assessment was independently made by 
each attending physician. The best treatment response 
of each patient was recorded. The ORR included the 
rate of complete response (CR) and partial response 
(PR), while DCR was defined as a sum of ORR and the 
rate of stable disease (SD). For survival analysis, the 
patient’s survival status, date of death, and date of 
last follow-up were recorded. The cut-off date of both 
survival and follow-up data was February 6, 2018. PFS 
was defined from the date of initiation of FOLFIRINOX to 
PD or death. The patients who survived and remained 
without PD were censored at the date of the last follow-
up. Patients who missed a follow-up without PD and 
with < a 6-mo follow-up period were censored at 6 mo 
from treatment initiation, even if deaths were confirmed 
after that. If a treatment switch occurred without PD, 
such as curative resection, irreversible electroporation, 
or another chemotherapeutic regimen, the date of 
switching treatment was considered as the censoring 
point. OS was always defined from the date of initiation 
of FOLFIRINOX to death. Patients whose deaths were 
not confirmed were censored at the date of the last 
follow-up. 
Assessment of adverse events
Treatment-related AE was also included in the se-
condary endpoints of this study. During the period 
of chemotherapy, treatment-related adverse events 
(AEs) were monitored and recorded by the attending 
physicians at each visit. All of the patients’ medical re-
cords on AEs were reviewed. The assessment of AEs 
was carried out in conformity with the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events version 4.03[19]. AEs leading to dose-reduction 
or dose-delay were recorded separately. 
Statistical analysis
For comparing the variables of both groups, Mann-
Whitney test was used for continuous variables and 
Pearson’s χ 2 test or Fisher’s exact test were used for 
categorical variables. For the analysis of survival data, 
the Kaplan-Meier method was used to estimate the 
median survival with a 95% confidence interval (CI) 
and the log-rank test was used for comparison. A 
423WJGO|www.wjgnet.com
Kang H et al . FOLFIRINOX for PC
November 15, 2018|Volume 10|Issue 11|
424
(70.5% vs 38.1%; P < 0.001); however, the rate of 
dose delay was not different between the two groups. 
Dose reduction due to neutropenia was higher in the 
sFOLFIRINOX group (60.2% vs 21.4%; P < 0.001), and, 
therefore, more patients were administered G-CSF 
(81.8% vs 64.3%; P = 0.028) and more G-CSF admini-
strations were performed during the treatment period 
[3.5 times (range: 0-24) vs 2 times (range: 0-12); P = 
0.043] than in the mFOLFIRINOX group.
Treatment responses and survivals
The ORR and DCR (primary end-points of this study) 
were not different between the two groups (Table 3). 
The median duration of follow-up was 10.3 mo in the 
sFOLFIRINOX group and 11.1 mo in the mFOLFIRINOX 
group (P = 0.181). The estimated median PFS of both 
groups were not different [sFOLFIRINOX: 8.7 mo 
(95%CI: 6.4-11.0) vs mFOLFIRINOX: 8.1 mo (95%CI: 
6.7-9.6), P = 0.272] (Figure 2A). The estimated median 
OS of the sFOLFIRINOX group was 13.9 mo (95%CI: 
11.5-16.4), and it was not different from that of the 
mFOLFIRINOX group [13.7 mo (95%CI: 9.5-17.9), P = 
0.476] (Figure 2B). Additionally, age and sex-adjusted 
HRs of the mFOLFIRINOX group to the sFOLFIRINOX 
group were not statistically significant [HR for disease 
progression or death, 1.36 (95%CI: 0.81-2.26), P = 
0.242; HR for death, 0.94 (95%CI: 0.55-1.60), P = 
0.813].
Treatment-related AEs
Severe (grade three or higher) treatment-related AEs 
Cox proportional-hazards model was used to estimate 
the adjusted hazard ratios (HR). P-value < 0.05 was 
considered statistically significant. All statistical analy-
ses were performed with IBM SPSS (version 23.0, IBM 
Corp., Armonk, NY, United States).
RESULTS
Patients and pretreatment characteristics
In total, 130 patients were included in the final analysis 
based on the inclusion and exclusion criteria. Of the 130 
patients, 88 were assigned to the sFOLFIRINOX group 
and 42 patients were assigned to the mFOLFIRINOX 
group. The detailed flow chart of patient selection is 
shown in Figure 1. When comparing the pretreatment 
characteristics, the mFOLFIRINOX group included more 
female patients (30.7% vs 57.1%; P = 0.004) and older 
patients [age (median), 57 vs 63.5; P = 0.018] than 
the sFOLFIRINOX group (Table 1). Other characteristics 
did not differ between the two groups. 
Treatment characteristics
The treatment characteristics are summarized in 
Table 2. The number of cycles administered and tre-
atment duration were not different between the two 
groups. The median relative dose intensities (RDIs) 
of each of the four agents were significantly higher in 
the sFOLFIRINOX group than in the mFOLFIRINOX 
group. The proportion of patients who experienced 
dose-reduction after the first cycle was larger in the 
sFOLFIRINOX group than in the mFOLFIRINOX group 
WJGO|www.wjgnet.com
Patients who met the inclusion 
criteria (n  = 193)
Excluded (n  = 63)
   Discontinued before response evaluation (n  = 28)
   1st cycle dose modification other than 75% of standard dose (n  = 13)
   Started the 1st cycle in another institution (n  = 12)
   Received other treatments during FOLFIRINOX (n  = 6)
   Prophylactic use of G-CSF (n  = 3)
   Active malignancy in other sites (n  = 1)
Patients who did not meet the 
exclusion criteria (n  = 130)
Standard-dose FOLFIRINOX
(n  = 88)
Modified-dose FOLFIRINOX 
(n  = 42)
Figure 1  Flow chart of patient selection. G-CSF: granulocyte colony stimulating factor.
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in the two groups are listed and compared in Table 4. 
Of the hematologic AEs, the rate of severe neutrope-
nia was significantly lower in the mFOLFIRINOX group 
than in the sFOLFIRINOX group (83.0% vs 66.7%; P = 
0.044). Other hematologic AE rates, including febrile 
neutropenia, were not different. Severe anorexia and 
diarrhea occurred less frequently in the mFOLFIRINOX 
group than in the sFOLFIRINOX group (48.9% vs 
28.6%; P = 0.029; 13.6% vs 0.0%; P = 0.009; 
respectively). All other non-hematologic severe AEs 
tended to occur less frequently in the mFOLFIRINOX 
group, with the exception of lung infection.
DISCUSSION
In this study, we aimed to retrospectively compare 
the therapeutic efficacy and safety of sFOLFIRINOX 
and mFOLFIRINOX as first-line chemotherapies for 
PC. To the best of our knowledge, this is the first direct 
comparative study that evaluated the efficacy and 
safety of sFOLFIRINOX and mFOLFIRINOX within a 
single institution. We observed that the median cycle 
and median duration of FOLFIRINOX were not different 
in both groups. Although the median RDI of all four 
agents were significantly less in the mFOLFIRINOX 
group, the therapeutic parameters such as ORR, DCR, 
OS, and PFS were not different between the two 
groups. Regarding the treatment-related AE profiles, 
severe neutropenia, anorexia, and diarrhea were re-
markably lower in the mFOLFIRINOX group than in the 
sFOLFIRINOX group. Therefore, our study supports 
dose modification from the initiation of treatment with-
out compromising treatment efficacy, particularly in 
elderly and female patients, who tend to show more 
WJGO|www.wjgnet.com
Table 1  Pretreatment characteristics
sFOLFIRINOX mFOLFIRINOX P value
(n  = 88) (n  = 42)
Sex, n (%)
   0.0041   Male 61 (69.3)  18 (42.9)
   Female 27 (30.7)  24 (57.1)
Age, yr    0.0181
Median (range)   57 (31-79) 63.5 (41-77)
ECOG-PS, n (%)
  0.426   0 68 (77.3)  35 (83.3)
   1 20 (22.7)    7 (16.7)
Laboratory test results, median (range)
Absolute neutrophil count, /μL         4200 (1610-11170)          4525 (2080-18930)   0.317
Hemoglobin, g/dL    12.3 (7.1-17.1)     12.1 (8.5-14.9) 0.36
Platelet count, × 103/μL   218 (76-439)      245 (107-764)   0.247
Total bilirubin, mg/dL    0.7 (0.2-4.8)     0.5 (0.2-2.7)   0.144
Albumin, g/dL    3.9 (2.8-5.0)     3.9 (2.4-4.8)   0.797
Creatinine, mg/dL      0.67 (0.37-1.02)       0.70 (0.37-1.04)   0.516
Level of CA 19-9
U/mL, median (range)        172.2 (0.6-20000.0)         455.5 (0.7-20000.0)   0.709
Normal, n (%) 17 (19.3)  11 (21.5)
  0.274Elevated, < 59 × ULN, n (%) 53 (60.2)  19 (45.2)
Elevated, ≥ 59 × ULN, n (%) 18 (20.5)  12 (28.6)
Biliary drainage, n (%)
  0.435
Presence 29 (33.0)  11 (26.2)
Tumor location in pancreas, n (%)
  0.657
   Head 40 (45.5)  16 (38.1)
   Body and tail 44 (50.0)  23 (54.8)
   Recurrent 4 (4.5)  3 (7.1)
Tumor size, cm
  0.313
Median (range)    3.6 (1.3-7.7)     4.0 (1.3-8.0)
Disease extent, n (%)
  0.243
Borderline resectable 17 (19.3)    6 (14.3)
Locally advanced 26 (29.5)    8 (19.0)
Metastatic 45 (51.1)  28 (66.7)
Stage, n (%)
  0.248
   Ⅱ 24 (27.3)    8 (19.0)
   Ⅲ 19 (21.6)    6 (14.3)
   Ⅳ 45 (51.1)  28 (66.7)
Prior treatment, n (%)
Naïve 75 (85.2)  33 (85.7)   0.941
Curative resection 4 (4.5)  4 (9.5)   0.272
CCRT   9 (10.2)  4 (9.5)   1.000
1Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; ECOG-PS: Eastern Cooperative 
Oncology Group performance status; ULN: Upper limit of normal range; CA: Carbohydrate antigen; CCRT: Concurrent chemoradiotherapy.
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study was less severe than sFOLFIRINOX. In addition, 
compared with that of the historical trial, the rate of 
severe diarrhea was lower, but the rates of severe 
neutropenia, febrile neutropenia, anemia, and vomiting 
were still higher in the mFOLFIRINOX.
Regarding neutropenia, 77.8% of patients ex-
perienced severe neutropenia in a Japanese phase 
Ⅱ study of sFOLFIRINOX for chemotherapy-naïve MPC, 
which is similar to our study’s findings[22]. In addition, 
most studies conducted in Asian countries reported 
severe neutropenia in > 65% of patients[23-26], which 
was more frequent than that in reports from western 
countries (11.0%-45.7%)[7,27-29]. These results suggest 
that Asians may be prone to severe FOLFIRINOX-re-
lated neutropenia, and dose adjustment is an option 
that should be considered when treating patients 
belonging to the Asian population. Unlike the present 
study, prophylactic G-CSF was routinely administered 
at every cycle in the aforementioned studies focusing 
on dose modification of FOLFIRINOX[13-17]. This dis-
tinction in therapeutic protocols should be considered 
when interpreting and comparing the rates of severe 
426
concern about treatment-related toxicities.
Currently, FOLFIRINOX is a universally-used first-line 
treatment for MPC[20,21], and it is also used for second-
line or neoadjuvant treatment. Owing to its severe 
toxicities (grade ≥ 3 neutropeniain 45.7% of patients; 
grade ≥ 3 fatigue in 23.6% of patients) reported in the 
PRODIGE4/ACCORD11 trial[7], treatment-related AE is 
a major concern when using FOLFIRINOX.
To reduce FOLFIRINOX-related toxicities, several 
groups have conducted studies focused on dose modi-
fication of FOLFIRINOX from the first cycle. Most of the 
FOLFIRINOX dose-modifying studies compared their 
results with the PRODIGE4/ACCORD11 trial. Retros-
pective research conducted in the UK using a reduced 
dose of irinotecan and omitting a 5-FU bolus reported 
a markedly lower rate of severe neutropenia than that 
in the historical trial, with similar rates of other severe 
AEs[15]. In a US phase Ⅱ trial using reduced doses of 
irinotecan and 5-FU bolus, the rates of severe neutro-
penia and vomiting were significantly lower than the 
rates in the historical trial; however, other severe AEs 
were similar[17]. The toxicity of mFOLFIRINOX in this 
WJGO|www.wjgnet.com
Table 2  Treatment characteristics
sFOLFIRINOX mFOLFIRINOX P value
(n  = 88) (n  = 42)
Number of cycles administered, median (range) 9.5 (4-24) 12 (4-32)   0.421
Treatment duration, d, median (range)    126 (42-322)   154 (42-434)   0.595
RDI to sFOLFIRINOX, %, median (range)
Oxaliplatin      85.3 (56.3-100)      75.0 (51.1-75.0) < 0.0011
Irinotecan      85.0 (56.3-100)      75.0 (51.1-75.0) < 0.0011
5-FU (bolus)      92.1 (21.4-100)      75.0 (51.1-75.0) < 0.0011
5-FU (infusion)      94.1 (56.3-100)      75.0 (51.1-75.0) < 0.0011
Patients with ≥ 1 dose reduction, n (%)  62 (70.5) 16 (38.1) < 0.0011
Cause of dose reduction (> 5%), n (%)
Neutropenia  53 (60.2)   9 (21.4) < 0.0011
Febrile neutropenia  10 (11.4) 4 (9.5)   1.000
Patients with ≥ 1 dose delay, n (%)  55 (62.5) 22 (52.4)   0.272
Cause of dose delay (> 5%), n (%)
Neutropenia  16 (18.2)   5 (11.9)   0.363
Febrile neutropenia  16 (18.2)   5 (11.9)   0.363
Fatigue  7 (8.0)   8 (19.0)   0.081
No. of G-CSF administered, median (range) 3.5 (0-24)   2 (0-12)    0.0431
Patients received G-CSF, n (%)  72 (81.8) 27 (64.3)    0.0281
1Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; RDI: Relative dose intensity; 5-FU: 
5-Fluorouracil; G-CSF: Granulocyte colony-stimulating factor.
Table 3  Response evaluation n  (%)
sFOLFIRINOX mFOLFIRINOX P value
(n  = 88) (n  = 42)
CR 1 (1.1) 1 (2.4)
PR 34 (38.6) 14 (33.3)
SD 36 (40.9) 20 (47.6)
PD 17 (19.3)   7 (16.7)
Objective responsea 35 (39.8) 15 (35.7) 0.656
Disease controlb 71 (80.7) 35 (83.3) 0.716
aObjective response includes CR and PR; bDisease control includes CR, PR, and SD. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard 
FOLFIRINOX; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.
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Table 4  Adverse events (≥ Grade 3) n  (%)
Event sFOLFIRINOX mFOLFIRINOX P value
(n  = 88) (n  = 42)
Hematologic
Neutropenia 73 (83.0) 28 (66.7)  0.0441
Febrile neutropenia 24 (27.3)   9 (21.4) 0.474
Anemia 19 (21.6) 11 (26.2) 0.561
Thrombocytopenia 8 (9.1) 2 (4.8) 0.499
Non-hematologic
Fatigue 33 (37.5) 14 (33.3) 0.644
Anorexia 43 (48.9) 12 (28.6)  0.0291
Nausea/Vomiting 53 (60.2) 19 (45.2) 0.108
Diarrhea 12 (13.6) 0 (0.0)  0.0091
Peripheral sensory neuropathy 12 (13.6) 2 (4.8) 0.224
Sepsis 5 (5.7) 0 (0.0) 0.174
Lung infection 3 (3.4) 4 (9.5) 0.212
Biliary tract infection 6 (6.8) 0 (0.0) 0.176
1Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX.
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Figure 2  Survival analyses and comparisons. A: Progression-free survival; B: Overall survival, according to the treatment group. mFOLFIRINOX: Modified 
FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX.
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mFOLFIRINOX in a single study. This could help clarify the clinical applicability 
of mFOLFIRINOX.
Research methods
The medical records of 130 pancreatic cancer patients [sFOLFIRINOX (n = 88), 
mFOLFIRINOX (n = 42)] were retrospectively reviewed. The objective response 
rate (ORR), disease control rate (DCR), progression-free survival (PFS), and 
overall survival (OS) were compared for efficacy analysis. Severe (≥ grade 
three) adverse event (AE) rates of the two groups were compared for toxicity 
analysis.
Research results
Although the median relative dose intensities of each of the drugs were 
significantly lower in the mFOLFIRINOX group, the response rates and survival 
were not different between the two groups (ORR: 39.8% vs 35.7%, P = 0.656; 
DCR: 80.7% vs 83.3%, P = 0.716; PFS: 8.7 mo vs 8.1 mo, P = 0.272; OS: 13.9 
mo vs 13.7 mo, P = 0.476). Severe AE rates, including neutropenia (83.0% vs 
66.7%; P = 0.044), anorexia (48.9% vs 28.6%; P = 0.029), and diarrhea (13.6% 
vs 0.0%; P = 0.009), were significantly lower in the mFOLFIRINOX group.
Research conclusions
In this direct comparative restrospective study, mFOLFIRINOX showed 
comparable efficacy to sFOLFIRINOX, with a better toxicity profile. Given the 
relatively high toxicity of sFOLFIRINOX, initiating FOLFIRINOX treatment, 
if clinically required, with 75% of the standard-dose could be an appropriate 
option to reduce toxicity concerns without compromising efficacy. 
Research perspectives
In the future, prospective comparative studies need to be conducted to 
determine the optimal dose modification of FOLFIRINOX and who will benefit 
from this strategy.
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neutropenia and neutropenic fever associated with 
mFOLFIRINOX in our study with those of prior research 
(67.9% vs 0%-12%; 26.4% vs 0%-5.6%; respectively). 
Regarding efficacy, previous studies using a modifi-
ed form of FOLFIRINOX showed 17.2%-46.7% of ORR 
and 80%-100% of DCR, which were similar to those of 
the PRODIGE4/ACCORD11 trial[13,15,17]. Our modification 
of FOLFIRINOX with 75% of the standard-dose was 
able to markedly reduce toxicity, and the efficacy was 
comparable with that of sFOLFIRINOX or previous stu-
dies, including the PRODIGE4/ACCORD11 trial. This 
therefore suggests that, in our study population, dose 
modification to reduce toxicity is possible without com-
promising treatment efficacy. 
There are certain limitations to this study. First, it 
has a retrospective study design. Although we selected 
patients based on strict exclusion criteria, the possibility 
of selection bias and information bias remains. Second, 
we included patients with BRPC and unresectable PC. 
When comparing the survival data with other trials, 
this characteristic of the patient population should be 
considered. Third, more females and older patients were 
included in the mFOLFIRINOX group. These differen-
ces may be attributed to the clinical characteristics of 
the patient, based on whether or not the attending 
physician decides to administer mFOLFIRINOX from the 
first cycle. These differences may affect the treatment 
outcome. A previous study reported that female gender 
could positively predict response to FOLFIRINOX in 
patients with advanced PC[30]. However, the prognostic 
significance of gender in PC remains controversial and 
warrants further evaluation[31]. Despite these limitations, 
this study is meaningful because it directly compares 
the two study groups, which underwent similar clinical 
practice within a single institution.
In conclusion, mFOLFIRINOX showed comparable 
efficacy to sFOLFIRINOX, with a better toxicity profile. 
Given the relatively high toxicity of sFOLFIRINOX, 
initiating FOLFIRINOX treatment, if clinically required, 
with 75% of the standard-dose can be an appropriate 
option to reduce toxicity concerns without compromising 
efficacy.
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for pancreatic cancer, its relatively high rate of adverse events is still a 
major concern. Several studies suggest that dose-modified FOLFIRINOX 
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